Everything below concerns HPLC-UV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-26. Numbers and descriptions here follow the published literature rather than marketing material.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
In January 2021, The government of Kenya unanimously passed the anti-doping bill into law that will enable the country to comply with the World 2021 anti-doping code. In April 2021, The US Senate passes the "United States Anti-Doping Agency Reauthorization Act of 2021" to reauthorize the United States Doping Agency.
== Nitrogen supplementation == Winemakers have long known that some fermentations ran more predictable and "healthier" if pomace (the solid skins, seeds and remains left after pressing) from another wine was added to the batch. This is a method still used today to make the Italian wine Ripasso. In 14th century Tuscany, the technique of governo used in some of the earliest Chiantis involved adding dried grapes to the batch. While that also added sugar both methods provided extra nitrogen and other nutrients still available in the skins and seeds.
{\displaystyle {\boldsymbol {\sigma }}=-\left[p-\left(\lambda +{\tfrac {2}{3}}\mu \right)\left(\nabla \cdot \mathbf {u} \right)\right]\mathbf {I} +\mu \left(\nabla \mathbf {u} +\left(\nabla \mathbf {u} \right)^{\mathrm {T} }-{\tfrac {2}{3}}\left(\nabla \cdot \mathbf {u} \right)\mathbf {I} \right)}
A plant morphologist makes comparisons between structures in many different plants of the same or different species. Making such comparisons between similar structures in different plants tackles the question of why the structures are similar. It is quite likely that similar underlying causes of genetics, physiology, or response to the environment have led to this similarity in appearance. The result of scientific investigation into these causes can lead to one of two insights into the underlying biology:
=== Lawsuits === On 12 January 2016, Dow Pharmaceutical Sciences and Valeant Pharmaceuticals North America LLC filed a lawsuit against Taro USA and Taro Industries, an Israel-based corporation. The lawsuit was filed for infringement upon their Onexton patent, by Taro attempting to submit an abbreviated new drug application (ANDA) to the Food and Drug Administration (FDA) for its generic 3.75% benzoyl peroxide and 1.2% clindamycin phosphate topical gel. The court concluded that Taro was guilty of attempting to submit an ANDA patent request before the Onexton patent expired. Perrigo settled its patent litigation with Valeant and Dow.
Sources: en.wikipedia.org
The journey across the United States began on 15 July 1988. On the journey he slept in bushes beneath the World Trade Center, camped outside Kennedy Airport in a tent, then headed west. On Staten Island he collapsed from heat exhaustion at 105 degrees Fahrenheit. In Utah the temperatures went down to minus 30 Fahrenheit. Carrying a tent and a backpack, with no backup, he walked alone to Niagara Falls, through Ontario in Canada, to Detroit, between the Great Lakes, across the Great Plains, through the Rockies in winter, to Yellowstone National Park, then south to the Grand Canyon, on to Las Vegas, through Death Valley and then snowshoed over the Sierras to reach San Francisco. In Death Valley, down to his last $13, Skinner found $200 in the desert, and he had $1 left when he crossed the Sierras to reach Yosemite Valley. The total distance he walked from New York City to San Francisco, was 4,952 miles (7,969 km). On the journey he visited 70 hospices and appeared on television, radio and in newspapers to encourage support for hospices across the U.S. and Canada. The mayor of San Francisco, Art Agnos, proclaimed 21 March 1989, "Colin Skinner Day," in recognition of the attention he brought to the work of hospices with AIDS patients in the city. Returning to Britain after this walk, he obtained a job as a research assistant in Chemical Pathology at the Middlesex Hospital and went on to obtain a PhD in Molecular Biology at University College London.
In 2019, Kennedy called on the Treasury Department to establish a website where citizens could find out whether they had unclaimed Treasury savings bonds. He established a similar website for the state of Louisiana when he was treasurer. On October 22, 2019, the Treasury Department announced that it would launch a website for unclaimed bonds. Kennedy said, "The bond might be lost, the physical bond in the days when we used paper bonds, and the people who loaned the money to the federal government might have forgotten about the bonds. But you know who knows about the bonds? The United States Department of Treasury, because they've got the names and the addresses, and right now they've got the money—$26 billion that they are holding that belongs to the American people, and they won't give it back." On November 25, 2019, Trump signed Kennedy's Recovery for Small Businesses After Disaster Act, a bill allowing small business disaster loans to remain at a limit of $25,000, rather than dropping to $14,000. After Justice Ruth Bader Ginsburg's death in 2020, Kennedy supported Trump's nomination of Amy Coney Barrett to fill the Supreme Court vacancy. Kennedy voted to confirm Barrett, and said in an interview on Tucker Carlson Tonight, "you would have to be barking mad to think that she is not qualified". After her confirmation on October 26, he applauded it as a "victory for our founders". On February 4, 2020, Kennedy voted against Trump's first impeachment.
They drove into the camp past FRELIMO guards to the parade ground where many were assembled before the attack commenced. The head of the Selous Scouts, Ronald Francis Reid-Daly, claimed that captured ZANLA documents showed that the people killed in the raid were either trained guerrillas or were undergoing guerrilla instruction and training. Paul L. Moorcraft and Peter McLaughlin wrote in 1982, that "although the camp did contain trained guerrillas and young recruits, many of its inhabitants were old people, women and young children who had fled from Rhodesia as refugees". They further wrote in 2010, that "although nearly all the personnel in the camp were unarmed, many were trained guerillas or undergoing instruction" and that documents captured from ZANLA, revealed more than 1,028 were killed in the operation. A 1994 Amnesty International publication described the operation as a massacre and stated that the camp at Nyadzonya housed refugees, and that a soldier who participated in the raid later stated: "We were told that Nyadzonia was a camp containing several thousand unarmed refugees who could be recruited to join the guerrillas. It would be easier if we went in and wiped them out while they were unarmed and before they were trained rather than waiting for the possibility of them being trained and sent back armed into Rhodesia". According to Amnesty International, 1,000 people were killed and the operation was "a gross human rights violation and a war crime".
=== Genome === As of early 2022, about 7 million SARS-CoV-2 genomes had been sequenced and deposited into public databases and another 800,000 or so were added each month. By September 2023, the GISAID EpiCoV database contained more than 16 million genome sequences. SARS-CoV-2 has a linear, positive-sense, single-stranded RNA genome about 30,000 bases long. Its genome has a bias against cytosine (C) and guanine (G) nucleotides, like other coronaviruses. The genome has the highest composition of U (uracil) (32.2%), followed by A (adenine) (29.9%), and a similar composition of G (19.6%) and C (18.3%). The nucleotide bias arises from the mutation of guanines and cytosines to adenines and uracils, respectively. The mutation of CG dinucleotides is thought to arise to avoid the zinc finger antiviral protein related defence mechanism of cells, and to lower the energy to unbind the genome during replication and translation (adenine and uracil base pair via two hydrogen bonds, cytosine and guanine via three). The depletion of CG dinucleotides in its genome has led the virus to have a noticeable codon usage bias. For instance, arginine's six different codons have a relative synonymous codon usage of AGA (2.67), CGU (1.46), AGG (.81), CGC (.58), CGA (.29), and CGG (.19). A similar codon usage bias trend is seen in other SARS–related coronaviruses.
In the mobilization stage, the stepparent can begin to step forward to address the family's process and structure. The tasks of this stage are to confront differences in each member's perception of the new family, as well as to influence one another before shaming or blaming begins to take action to reorganize the family structure. The goal here is to make joint decisions about new stepfamily rituals, rules, and roles. The focus in this stage is on the stepfamily's unique "middle ground" (i.e. the "areas of shared experience, shared values, and easy cooperative functioning created over time"), and on balancing this new middle ground with honoring of past and other relationships. The later stages consist of the contact and resolution stages. In the contact stage, the couple is working well together, the boundaries between households are clear, and stepparents have definite roles with stepchildren as "intimate outsiders." The task for this stage is in solidifying the stepparent's role, and in continuing the process of awareness. Finally, in the resolution stage, the stepfamily's identity has become secure. The family accepts itself for who it is, there is a strong sense of the stepfamily's middle ground, and children feel secure in both households. The task for this stage is to nourish the depth and maturity gained through this process, and to rework any issues that might arise at family "nodal events" (e.g., weddings, funerals, graduations, etc.).
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.